次世代がん診断技術の世界市場:先進PCR技術、CTC検査、FISH検査、マイクロアレイ、次世代シークエンシング技術...市場調査レポートについてご紹介

【英文タイトル】Next-Generation Cancer Diagnostics Market Forecast 2015-2025 : Opportunities for Leading Companies Developing Advanced PCR Techniques, CTC tests, FISH tests, Microarrays and NGS Technologies

▼当市場調査レポートの詳細内容確認、お問い合わせ及びご購入申込は下記ページでお願いします。▼マーケットレポート

【レポートの概要(一部)】

1. Executive Summary
1.1 Overview of Findings
1.2 Structure of the Report
1.3 Global Next-Generation Cancer Diagnostics Market Segmentation
1.4 Why You Should Read This Report
1.5 How This Report Delivers
1.6 Key Questions Answered by This Analytical Report
1.7 Who is This Report For?
1.8 Methodology
1.9 Frequently Asked Questions (FAQ)
1.10 Associated Visiongain Reports
1.11 About Visiongain

2. Introduction to Next-Generation Cancer Diagnostics
2.1 What Is Cancer?
2.2 Cancer Diagnostics: An Overview
2.2.1 Screening
2.2.2 Diagnosis
2.2.3 Staging
2.3 Cancer Diagnosis Methods
2.3.1 Physical Examination
2.3.2 Imaging Techniques
2.3.2.1 Ultrasound
2.3.2.2 Computed Tomography (CT)
2.3.2.3 Magnetic Resonance Imaging (MRI)
2.3.2.4 Positron Emission Tomography (PET)
2.3.3 Histopathological and Cytological Techniques
2.3.4 Immunohistochemistry (IHC) Analysis
2.3.5 Circulating Tumour Cell (CTC) Analysis
2.3.6 Molecular Diagnostics and IVD
2.3.6.1 Polymerase Chain Reaction (PCR)
2.3.6.2 Multiplex PCR
2.3.6.3 Real-Time PCR (RT-PCR or qPCR)
2.3.6.4 Digital PCR (dPCR)
2.3.6.5 In Situ Hybridisation (ISH)
2.3.6.6 Microarray
2.3.6.7 Next-Generation Sequencing (NGS)
2.4 Tests for Inherited and Acquired Genetic Mutations
2.5 Companion Diagnostics (CDx)
2.6 Laboratory Developed Test (LDT)
2.7 Precision Medicine
2.8 Government Regulations
2.8.1 The US Approval and Regulation System
2.8.2 The EU Approval and Regulation System
2.9 Market Definition

3. Next-Generation Cancer Diagnostics: World Market 2015-2025
3.1 The Global Next-Generation Cancer Diagnostics Market: Overview
3.2 The Global Next-Generation Cancer Diagnostics Market Forecast 2015-2025
3.3 How Will Segmental Market Shares Change to 2025?
3.4 Biomarkers and Molecular Diagnostics
3.4.1 Biomarkers and Diagnostic Tests for Breast Cancer
3.4.2 Biomarkers and Diagnostic Tests for Prostate Cancer
3.4.3 Biomarkers and Diagnostic Tests for Colorectal Cancer
3.5 Companion Diagnostics and Collaborations between Two Industries
3.6 LDTs to be Replaced by Approved Tests
3.7 Decentralisation of Diagnostic Tests
3.8 Next-Generation Cancer Diagnostics: Drivers and Restraints 2015-2025

4. Next-Generation Cancer Diagnostics Submarkets 2015-2025
4.1 Advanced PCR Techniques
4.1.1 Advanced PCR Techniques Market Forecast 2015-2025
4.1.2 Leading Products in the Real-Time PCR Market
4.1.2.1 cobas 4800 System & Oncology Tests (Roche)
4.1.2.2 QuantStudio Dx & 7500 Fast Dx (Thermo Fisher)
4.1.2.3 Rotor-Gene Q & therascreen Tests (Qiagen)
4.1.2.4 Oncotype DX (Genomic Health)
4.1.3 Leading Products in the Digital PCR Market
4.1.4 Pap Tests Being Replaced by PCR Assays
4.1.5 Advanced PCR-Based Techniques: Drivers and Restraints 2015-2025
4.2 In Situ Hybridisation (ISH)
4.2.1 ISH Cancer Diagnostics Market Forecast 2015-2025
4.2.2 Leading Products in the ISH Cancer Diagnostics Market
4.2.3 HER2 Tests for Breast Cancer
4.2.4 ISH Cancer Diagnostics: Drivers and Restraints 2015-2025
4.3 Circulating Tumour Cells (CTCs) Analysis
4.3.1 CTCs Analysis Market Forecast 2015-2025
4.3.2 Leading Product in the CTCs Analysis Market
4.3.2.1 CellSearch System (Janssen Diagnostics)
4.3.3 Epic Sciences and LabCorp to Expand in Asia Markets
4.3.4 CTCs Separation by Ultrasound
4.3.5 CTC Clusters More Likely to Cause Metastasis?
4.3.6 CTCs Analysis: Drivers and Restraints 2015-2025
4.4 Microarray
4.4.1 Microarray Cancer Diagnostics Market Forecast 2015-2025
4.4.2 Leading Products in the Microarray Market
4.4.2.1 OncoScan FFPE Assay Kit (Affymetrix)
4.4.2.2 MammaPrint (Agendia)
4.4.3 Microarray Cancer Diagnostics: Trends and Developments
4.4.3.1 Array Comparative Genomic Hybridisation (Array CGH)
4.4.4 Microarray Cancer Diagnostics: Drivers and Restraints 2015-2025
4.5 Next-Generation Sequencing (NGS)
4.5.1 NGS Cancer Diagnostics Market Forecast 2015-2025
4.5.2 Leading Products in the NGS Market
4.5.2.1 MiSeqDx (Illumina)
4.5.2.2 Ion PGM Dx System (Thermo Fisher)
4.5.2.3 GeneRead DNAseq Targeted Panels V2 (Qiagen)
4.5.3 NGS Cancer Diagnostics: Trends and Developments
4.5.3.1 Myriad Shifting from PCR to NGS Panel
4.5.3.2 Competition in the NGS Market
4.5.3.3 Bio-Rad to Commercialise NGS system for Clinical Use
4.5.3.4 Qiagen Launched NGS Bioinformatics Platform
4.5.4 NGS Cancer Diagnostics: Drivers and Restraints 2015-2025

5. Leading National Markets 2015-2025
5.1 World Next-Generation Cancer Diagnostics Market: Regional Forecast 2015-2025
5.1.1 How Will Regional Market Shares Change to 2025?
5.2 US Next-Generation Cancer Diagnostics Market Forecast 2015-2025
5.2.1 FDA Provides Guidance for Molecular Diagnostic Instruments with Combined Functions
5.2.2 Obama Launched ‘Precision Medicine Initiative’
5.2.3 FDA and CMS to Regulate LDTs
5.3 EU5 Next-Generation Cancer Diagnostics Market Forecast 2015-2025
5.3.1 Germany: Leading Market in the EU
5.3.2 France: Reduction in Healthcare Spending
5.3.3 UK: 100,000 Genomes Project
5.3.4 Spain: Recovering from Financial Crisis
5.3.5 Italy: Decreasing Reimbursement
5.4 Japanese Next-Generation Cancer Diagnostics Market Forecast 2015-2025
5.4.1 Takeda Collaborated with NCC in Genomic Screening Project
5.4.2 Qiagen Partnered Hitachi on PCR and NGS Technologies
5.4.3 Increase Cancer Rates in Fukushima after Nuclear Disaster?
5.5 Chinese Next-Generation Cancer Diagnostics Market Forecast 2015-2025
5.5.1 Illumina Entering the Chinese Market
5.5.2 Epigenomics Colorectal Cancer Test Approved in China
5.5.3 China Offered Free Screenings for Cervical and Breast Cancer
5.6 Indian Next-Generation Cancer Diagnostics Market Forecast 2015-2025
5.6.1 Lack of Genetic Testing Regulation
5.6.2 Cancer Genetics Launched NGS Cancer Panel in India
5.7 Brazilian Next-Generation Cancer Diagnostics Market Forecast 2015-2025
5.8 Russian Next-Generation Cancer Diagnostics Market Forecast 2015-2025
5.8.1 IBM’s Collaboration with Russian Companies to Advance Clinical Decision Making

6. Leading Companies in the Next-Generation Cancer Diagnostics Market 2015
6.1 Roche Diagnostics
6.1.1 Roche Diagnostics: Product Portfolio, 2015
6.1.2 Roche Diagnostics: Diagnostics Outlook
6.1.3 Cobas HPV Test Approved in the US in 2014
6.1.4 Roche Diagnostics: Recent M&A Activity
6.1.5 Roche Coming Back to the NGS Business?
6.2 Abbott Laboratories
6.2.1 Abbott: Next-Generation Cancer Diagnostics Product Portfolio 2015
6.2.2 Abbott: Diagnostics Outlook
6.2.3 Abbott Obtained Exclusive License for Bladder Cancer Biomarker FGFR3
6.3 Qiagen
6.3.1 Qiagen: Next-Generation Cancer Diagnostics Product Portfolio 2015
6.3.1.1 Molecular Diagnostics Kits
6.3.1.2 Real-Time PCR: Rotor-Gene Q
6.3.1.3 Bioinformatics for NGS
6.3.2 Qiagen: Market Outlook
6.3.3 HalioDx Created from Qiagen Marseille
6.4 Thermo Fisher Scientific
6.4.1 Thermo Fisher Scientific: Business Segments
6.4.2 Thermo Fisher: Next-Generation Cancer Diagnostics Product Portfolio 2015
6.4.2.1 QuantStudio 3D (Digital PCR)
6.4.2.2 In Situ Hybridisation
6.4.2.3 Microarray Slides
6.4.2.4 Next-Generation Sequencing
6.4.2.5 Real-Time PCR for Oncology in Pipeline?
6.4.3 Thermo Fisher: Life Sciences Outlook
6.4.4 NGS Oncomine Focus Assay for Oncology Research
6.5 Agilent Technologies
6.5.1 Agilent: Next-Generation Cancer Diagnostics Product Portfolio 2015
6.5.1.1 NGS Enrichment Platforms
6.5.1.2 Cytogenetic Research and Microarrays
6.5.1.3 Other Products
6.5.2 Agilent: Life Sciences and Diagnostics Outlook
6.5.3 Partnerships and Collaborations for Companion Diagnostics
6.6 Hologic
6.6.1 Hologic: Next-Generation Cancer Diagnostics Product Portfolio 2015
6.6.1.1 Aptima HPV Assay and Cervista HPV Assay
6.6.1.2 Progensa PCA3 Assay
6.6.2 Hologic: Diagnostics Sales Outlook
6.7 Illumina
6.7.1 Illumina: Technology and Product Portfolio 2015
6.7.1.1 Sequencing Technology
6.7.1.2 BeadArray Microarray
6.7.1.3 Consumables
6.7.1.4 Services
6.7.2 Illumina: Sales Outlook
6.7.3 Illumina: Recent M&A Activity
6.7.4 Joined Forces with UK Government for 100,000 Genomes Project
6.7.5 Partnered with Merck Serono to Develop NGS Cancer Diagnostics
6.7.6 Investing on Synthetic DNA Manufacturing Technology
6.8 Myriad Genetics
6.8.1 Myriad: Next-Generation Cancer Diagnostics Product Portfolio 2015
6.8.2 Myriad: Sales Outlook
6.8.3 New Landscape in the BRCA Diagnostic Market

7. Qualitative Analysis of the Next-Generation Cancer Diagnostics Market 2015-2025
7.1 SWOT Analysis of the Next-Generation Cancer Diagnostics Market
7.2 Strengths
7.2.1 Global Cancer Rates Set to Soar
7.2.2 Increasing Awareness of Molecular Cancer Diagnostics
7.2.3 The Trend in Precision Medicine
7.3 Weaknesses
7.3.1 Industry Facing Increasing Reimbursement Pressure
7.3.2 Physicians’ Reliance on Traditional Methods
7.4 Opportunities
7.4.1 Expanding Biomarkers and Cancer Test Menus
7.4.2 Emerging Market to Provide Future Growth
7.4.3 Companion Diagnostics on the Rise
7.5 Threats
7.5.1 Decreasing Healthcare Spending
7.5.2 Gene Patenting Banned in the US?

8. Research Interviews
8.1 Keith Cannon, Executive Vice President, Aviva Biosciences
8.1.1 Aviva: From Research Laboratories to Clinical and Diagnostic Markets
8.1.2 Ability to Distinguish CTCs is the Key
8.1.3 RedSift(TM): Automated Enrichment of Nucleated Cells
8.1.4 On Drivers and Restraints in the CTC Technologies Market
8.1.5 On the Growth in Regional Markets
8.2 Nobuyoshi Katagiri, Ph.D., Director, Diagnostics Development Department, Oncolys BioPharma
8.2.1 On Future Growth of Oncolys BioPharma
8.2.2 CTCs is Changing the Market
8.2.3 On Current Restraints in the Market
8.2.4 ctDNA May Compete with Oncolys BioPharma’s TelomeScan

9. Conclusions
9.1 The World Next-Generation Cancer Diagnostics Market
9.1.1 Current Leading Next-Generation Cancer Diagnostics Segments
9.1.2 Notable Next-Generation Cancer Diagnostics Companies
9.1.3 Leading Regional Markets
9.1.4 World Next-Generation Cancer Diagnostics Market Forecast 2015-2025
9.2 The Future of the Next-Generation Cancer Diagnostics Market

10. Glossary


【レポート販売概要】

■ タイトル:次世代がん診断技術の世界市場:先進PCR技術、CTC検査、FISH検査、マイクロアレイ、次世代シークエンシング技術
■ 英文:Next-Generation Cancer Diagnostics Market Forecast 2015-2025 : Opportunities for Leading Companies Developing Advanced PCR Techniques, CTC tests, FISH tests, Microarrays and NGS Technologies
■ 発行日:2015年7月
■ 調査会社:visiongain
■ 商品コード:VGAIN5081913
■ 調査対象地域:グローバル
※当サイトは世界の市場調査レポート紹介サイトです。市場規模、市場動向、市場予測など、多様な分析データを含むグローバル調査レポートをご案内致します。日本国内を含むアジア太平洋、中国、ヨーロッパ、アメリカ、北米、中南米、中東、アフリカ地域などにおける、製品、サービス、技術、企業(メーカー、ベンダー)、市場シェア、市場環境など多様な項目に対応致します。当サイトでご紹介するレポートは「市場調査レポート販売サイトのMarketReport.jp」でお問い合わせ及びご購入可能です。